Opus Genetics Q1 net loss $65.5M; cash $60M; enters $35M Oberland debt facility

Opus Genetics, Inc.

2026-Q1 EPS reported -$0.75 revenue$2,157,000

Net loss $65.5M ($0.75 per share) vs $8.2M loss a year ago; includes non-cash warrant liability fair value change.
Revenue $2.2M from Viatris collaboration, down from $4.4M.
Cash $60M at March 31; post-quarter $35M senior secured notes from Oberland Capital plus $5M equity; total ~$90M funds into 2029.
LCA5 program accepted into FDA's RDEP program; pivotal Phase 3 enrollment ongoing, dosing expected Q4 2026.
BEST1 Cohort 1 topline data expected September 2026; R&D Science Forum June 16.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Opus Genetics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026 , Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026 .

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-033856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.